Welcome : Guest

Press Release


January 10, 2017 – Cost Containment Measures from Pharma Companies to Drive the Pharmaceutical Contract Manufacturing Market, According to a New Report by Global Industry Analysts, Inc.

GIA launches comprehensive analysis of industry segments, trends, growth drivers, market share, size and demand forecasts on the global Pharmaceutical Contract Manufacturing market. The global market for Pharmaceutical Contract Manufacturing is projected to reach US$25.3 billion by 2022, driven by the growing focus on cost containment as pharmaceutical companies face shrinking profit margins as a result of growing competition from generics and biosimilars, patent expiry of blockbuster drugs and the ensuing aggravation of pricing pressures and the competitive need to increase time-to-market through resource management.

Dynamics in the pharmaceutical industry have altered significantly over the years, driven by myriad factors, which make pharma outsourcing a necessity. Driven by multitude of competitive forces, the pharmaceutical industry is under extreme pressure to improve productivity and reduce cost of drug discovery research and drug production. CMOs/CDMOs in this regard are growing in prominence as increasingly important elements in the pharma value chain. Fewer blockbuster drugs, increasing generic incursion, growing pricing pressures, rising cost of drug development, growing stringency in regulations, and the increasing need for advanced production technologies among others have considerably strained financial resources of pharmaceutical companies, pushing cost containment measures to the fore. Pharmaceutical contract manufacturing (PCM) offers cost-effective means of producing pharmaceutical products, as it eliminates the need for pharmaceutical companies to invest in facilities, labor, and new manufacturing technologies.

Contract manufacturing also provides the added benefit of scalable production capacity, technical resource expansion, geographical reach and risk reduction during demand fluctuations.

Increasing number of specialized and orphan drugs are leading to fewer high-volume drugs, in turn resulting in small batch productions and small-volume contracts for contract manufacturing organizations (CMOs). Another trend in the market is the growing complexity of new drugs under development, particularly those focusing on using high potency API (HPAPIS) and addressing poor water solubility of drugs, which is compelling CMOs to acquire additional expertise and technological capabilities to remain relevant in the business and achieve growth. With pharma companies increasingly leaning towards contracting partners with more comprehensive service offerings, CMOs are espousing vertical integration by acquiring upstream research and development capabilities. In the biopharmaceutical contract manufacturing space, the market is expected to witness higher prospects for Antibody-drug conjugates (ADCs) due to current capacity constraints in the pharmaceutical industry. At the technology level, the market is witnessing increasing shift towards perfusion cell culture, away from fed-batch processes, due to inherent benefits of higher efficiency and cost reduction.

As stated by the new market research report on Pharmaceutical Contract Manufacturing, the United States represents the largest market worldwide supported by aggressive healthcare reforms, migration to value based healthcare, growing pricing pressures triggered by replacement of branded drugs with generics, increasing market for biologicals, and emergence of biosimilars. Asia-Pacific ranks as the fastest growing market with a CAGR of 8.2% through the analysis period led by the emergence of low cost Asian countries with huge talent pool as hubs for outsourced services. Solid Dosage Forms represents the largest market segment by dosage form, supported by the development of several advanced new chemical entities and growing market for generic drugs. The plethora of biologics under development, migration from vials to flexible-bag and pre-filled syringes systems, and changing regulations are expected to drive demand for injectables contract manufacturing with sterile injectables forecast to witness the strongest potential for future growth.

Major players covered in the report include Aenova Group, Ajinomoto Althea, Inc., Albany Molecular Research Inc., Alcami Corporation, Boehringer Ingelheim GmbH, Baxter International, Inc., Catalent Pharma Solutions, Inc., Cobra Biologics Holding AB, CordenPharma International, Dishman Group, DPx Holdings B.V., Fareva Group, Famar Health Care Services, Hospira, Inc., Jubilant Life Sciences Limited, Kemwell Biopharma Pvt. Ltd., Lonza Group Ltd., LTS Lohmann Therapie-Systeme AG, NextPharma Technologies Holding Ltd., Nipro Pharma Corporation, Recipharm AB and Vetter Pharma International GmbH among others.

The research report titled “Pharmaceutical Contract Manufacturing: A Global Strategic Business Report” announced by Global Industry Analysts Inc., provides a comprehensive review of market trends, issues, drivers, mergers, acquisitions and other strategic industry activities of global companies. The report provides market estimates and projections for Pharmaceutical Contract Manufacturing consumption in terms thousand cubic meters for all major geographic markets such as United States, Canada, Japan, Europe (France, Germany, Italy, UK, Spain, and Rest of Europe), Asia-Pacific and Rest of World. Dosage forms analyzed in the report include Injectables, Solid Dosage Forms and Liquid & Semi-solid Dosage Forms.


» View Complete Report Details

« Back